Charles River Laboratories Intl. Inc vs Wynn Resorts, Limited — how do they compare? Charles River Laboratories Intl. Inc trades at $302.17 (market cap $14.23B), while Wynn Resorts, Limited trades at $75.32 (market cap $7.75B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap, and Wynn Resorts, Limited pays a 1.33% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Wynn Resorts, Limited for 76 Days on average.
| CRL | WYNN | |
|---|---|---|
Market Cap | $14.23B | $7.75B |
Volume | 1,176,885 | 2,243,813 |
Sector | Health | Consumer Cyclical |
52-Week High | $310.77 | $133.09 |
52-Week Low | $149.93 | $74.97 |
Typical Hold Time | 33 Days | 76 Days |
Enterprise Value | $17.06B | $17.99B |
Dividend Yield | — | 1.33% |
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
Wynn Resorts (WYNN) trades at $75.24, up 0.36% with bearish technical signals from moving averages. The company reported mixed Q2 2026 earnings, beating EPS estimates but showing margin pressure in U.S. operations. Revenue growth is driven by Macau strength, while significant capital expenditures for new projects in the UAE create cash flow challenges. Analyst consensus remains strongly bullish with a $132.36 price target despite recent earnings volatility and high debt levels.
Investment outlook balances strong Macau recovery against rising capex risks. The stock offers 76% upside to consensus target but faces execution risks on new projects and persistent debt burden. Near-term catalysts include Q3 earnings and UAE project developments, while margin compression and economic sensitivity remain key concerns for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →